Xanthomatosis Cerebrotendinous

Download PDF

Recent Publications on Xanthomatosis Cerebrotendinous:
The first cerebrotendinous xanthomatosis family from Argentina: a new mutation in CYP27A1 gene. Fox-Fordyce disease is a rare skin condition characterized by the presence...	1st March, 2008	FESEN, Laboratorio de Neuroquimica, Buenos Aires, Argentina.	Neurology. 2008 Jan 29;70(5):402-4. DOI Direct Link
Effectors of rapid homeostatic responses of endoplasmic reticulum cholesterol and 3-hydroxy-3-methylglutaryl-CoA reductase. The cholesterol content of the endoplasmic reticulum (ER) and the activity...	15th February, 2008	Department of Pathology, Rush University Medical Center, 1653 W. Congress	J Biol Chem. 2008 Jan 18;283(3):1445-55. Epub 2007 Nov 16. DOI Direct Link
Cerebrotendinous xanthomatosis: a treatable cause of metabolic ataxia. Cerebrotendinous xanthomatosis is an exceptionally rare condition in...	9th January, 2008	Department of Medicine, K.J. Somaiya Medical College and Research Centre,	J Assoc Physicians India. 2007 Sep;55:655-7.
Cerebrotendinous xanthomatosis: case report with evidence of oxidative stress. Cerebrotendinous xanthomatosis is an autosomal recessive disorder of bile...	14th November, 2007	Department of Pathology, University of Maryland, Baltimore, Maryland, USA.	Redox Rep. 2007;12(3):119-24. DOI Direct Link
Mutational analysis of CYP27A1: assessment of 27-hydroxylation of cholesterol and 25-hydroxylation of vitamin D. The CYP27A1 gene encodes a mitochondrial enzyme that modulates the acidic...	10th October, 2007	Department of Medicine, Medical University of South Carolina, Strom	Metabolism. 2007 Sep;56(9):1248-55. DOI Direct Link
→View more research publications.

BioNews Results for Xanthomatosis Cerebrotendinous:
Sigma-Tau acquires Chenofalk from Germany-based Dr Falk Pharma	PharmaBiz:  Jul 12 2008 10:33AM Matching: xanthomatosis cerebrotendinous
Sigma-Tau Pharmaceuticals seeking FDA approval of medicine for rare genetic disease affecting less than 100 Am	Checkbiotech:  Jul 10 2008 12:06PM Matching: xanthomatosis cerebrotendinous
Sigma-Tau Pharmaceuticals Seeking FDA Approval of Medicine for Rare Genetic Disease Affecting Less Than 100 Am	Genetic Engineering News:  Jul 9 2008 6:52PM Matching: xanthomatosis cerebrotendinous
Sigma-Tau Pharmaceuticals Seeking FDA Approval of Medicine for Rare Genetic Disease Affecting Less Than 100 Am	Street Insider:  Jul 9 2008 6:51PM Matching: xanthomatosis cerebrotendinous
Sigma-Tau Pharmaceuticals Seeking FDA Approval of Medicine for Rare Genetic Disease Affecting Less Than 100 Am	Houston Chronicle:  Jul 9 2008 6:32PM Matching: xanthomatosis cerebrotendinous
Promote your company here: BioNewsCast - Press Release Distribution	→View more news.

BioPortfolio Ltd. offers e-mail and postal lists for Xanthomatosis Cerebrotendinous scientists - we have details of around 15 individuals working on Xanthomatosis Cerebrotendinous .

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.